These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288 [TBL] [Abstract][Full Text] [Related]
11. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP; Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832 [TBL] [Abstract][Full Text] [Related]
12. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO) Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369 [TBL] [Abstract][Full Text] [Related]
13. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123 [TBL] [Abstract][Full Text] [Related]
15. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study. Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939 [No Abstract] [Full Text] [Related]
16. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Allegretti JR; Barnes EL; Stevens B; Storm M; Ananthakrishnan A; Yajnik V; Korzenik J Dig Dis Sci; 2017 Jun; 62(6):1590-1596. PubMed ID: 28357697 [TBL] [Abstract][Full Text] [Related]
17. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028 [TBL] [Abstract][Full Text] [Related]
18. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Kotze PG; Ma C; Almutairdi A; Al-Darmaki A; Devlin SM; Kaplan GG; Seow CH; Novak KL; Lu C; Ferraz JGP; Stewart MJ; Buresi M; Jijon H; Mathivanan M; Heatherington J; Martin ML; Panaccione R Aliment Pharmacol Ther; 2018 Sep; 48(6):626-637. PubMed ID: 30063077 [TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935 [TBL] [Abstract][Full Text] [Related]
20. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]